Dr. Saba is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5700 Martin Luther King Jr. Way
Oakland, CA 94609Phone+1 510-414-6317- Is this information wrong?
Education & Training
- University of Maryland School of MedicineClass of 1985, MD
Certifications & Licensure
- CA State Medical License 1999 - 2025
Clinical Trials
- SPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International) Start of enrollment: 2020 Jun 30
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis.Babak Oskouian, Joanna Y Lee, Shahab Asgharzadeh, Ranjha Khan, Meng Zhang, Julia R Weisbrod, Youn-Jeong Choi, Latika Puri, Ana E Aguilar, Piming Zhao, Julie D Saba> ;Oncogene. 2024 Apr 1
- 1 citationsAAV-SPL 2.0, a Modified Adeno-Associated Virus Gene Therapy Agent for the Treatment of Sphingosine Phosphate Lyase Insufficiency Syndrome.Ranjha Khan, Babak Oskouian, Joanna Y Lee, Jeffrey B Hodgin, Yingbao Yang, Gizachew Tassew, Julie D Saba> ;International Journal of Molecular Sciences. 2023 Oct 25
- 5 citationsSphingosine phosphate lyase insufficiency syndrome: a systematic review.Zahra Pournasiri, Abbas Madani, Fatemeh Nazarpack, John A Sayer, Zahra Chavoshzadeh, Fatemeh Nili, Paulina Tran, Julie D Saba, Mahnaz Jamee> ;World Journal of Pediatrics. 2023 May 1
- Join now to see all
Press Mentions
- Newly Discovered Role of AF1q in NeuroblastomaMarch 5th, 2024
- New Paediatric Cancer Marker, New Hope for a Treatment TargetMarch 5th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: